Prostatic Neoplasms

Showing 26 - 50 of 380

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Prostatic Tumors Trial in Worldwide (Radium-223 dichloride (Xofigo, BAY88-8223), Matching (normal saline), Abiraterone)

Active, not recruiting
  • Prostatic Neoplasms
  • Radium-223 dichloride (Xofigo, BAY88-8223)
  • +3 more
  • Anchorage, Alaska
  • +163 more
Jan 18, 2023

Prostatic Tumors Trial in Worldwide (Apalutamide, Abiraterone acetate, Prednisone)

Active, not recruiting
  • Prostatic Neoplasms
  • Phoenix, Arizona
  • +183 more
Jan 17, 2023

Prostatic Tumors, Metastatic Castration-Resistant Prostate Cancer Trial in Worldwide (Abiraterone Acetate, Prednisone,

Active, not recruiting
  • Prostatic Neoplasms
  • Metastatic Castration-Resistant Prostate Cancer
  • Abiraterone Acetate
  • +2 more
  • Los Angeles, California
  • +6 more
Jan 18, 2023

Prostatic Tumors Trial in Beijing, NanJing, ShangHai (Apalutamide)

Active, not recruiting
  • Prostatic Neoplasms
  • Beijing, China
  • +3 more
Jan 17, 2023

Prostatic Tumors Trial in Worldwide (Radiotherapy, LHRHa, Apalutamide)

Recruiting
  • Prostatic Neoplasms
  • Radiotherapy
  • +2 more
  • Tucson, Arizona
  • +145 more
Jan 17, 2023

Treatment Satisfaction With Ra-223 in Japan

Active, not recruiting
  • Prostatic Neoplasms
  • Radium-223 dichloride (Xofigo, BAY88-8223)
  • Multiple Locations, Japan
    Many Locations
Jan 12, 2023

Combined mpMRI and PSMA PET/CT for Highly Suspicious Patients

Not yet recruiting
  • Prostatic Neoplasms
  • +2 more
    • (no location specified)
    Jan 9, 2023

    Prostatic Tumors Trial in Worldwide (Darolutamide (Nubeqa, BAY1841788), Placebo, Androgen deprivation therapy (ADT))

    Active, not recruiting
    • Prostatic Neoplasms
    • Darolutamide (Nubeqa, BAY1841788)
    • +2 more
    • Macquarie University, New South Wales, Australia
    • +131 more
    Jan 5, 2023

    Prostatic Tumors, Exercise, Castration-resistant Prostate Cancer Trial in Ghent (Exercise)

    Completed
    • Prostatic Neoplasms
    • +3 more
    • Exercise
    • Ghent, Oost-Vlaanderen, Belgium
      University Hospital ghent
    Dec 22, 2022

    Fasting, Prostatic Tumors Trial in Berlin (Fasting, Control)

    Completed
    • Fasting
    • Prostatic Neoplasms
    • Fasting
    • Control
    • Berlin, Germany
      Charité Centrum Chirurgische Medizin, CC 8 Klinik für Urologie
    Dec 12, 2022

    Prostatic Tumors, Castration-Resistant Trial (64Cu-SAR-BBN, 67Cu-SAR-BBN)

    Not yet recruiting
    • Prostatic Neoplasms
    • Castration-Resistant
    • (no location specified)
    Dec 1, 2022

    Prostatic Tumors Trial in Worldwide (Pembrolizumab, Docetaxel, Prednisone)

    Active, not recruiting
    • Prostatic Neoplasms
    • Pembrolizumab
    • +4 more
    • Mobile, Alabama
    • +214 more
    Nov 24, 2022

    Prostatic Tumors Trial in Worldwide (Pembrolizumab, Enzalutamide, Placebo)

    Active, not recruiting
    • Prostatic Neoplasms
    • Pembrolizumab
    • +2 more
    • Mobile, Alabama
    • +257 more
    Nov 22, 2022

    Prostatic Tumors, Castration-Resistant, Tumors by Histologic Type, Tumors, Prostate Trial in United States (P-PSMA-101 CAR-T

    Active, not recruiting
    • Prostatic Neoplasms, Castration-Resistant
    • +16 more
    • Duarte, California
    • +9 more
    Nov 15, 2022

    Prostatic Tumors Trial in Worldwide (EPI-7386, Abiraterone Acetate, Prednisone or Prednisolone)

    Suspended
    • Prostatic Neoplasms
    • Towson, Maryland
    • +3 more
    Nov 3, 2022

    Prostate Cancer, Prostate Adenocarcinoma, Prostatic Tumors Trial in Montreal (131I-PSMA-1095 Radioligand Therapy (RLT))

    Active, not recruiting
    • Prostate Cancer
    • +5 more
    • 131I-PSMA-1095 Radioligand Therapy (RLT)
    • Montreal, Quebec, Canada
      Stephan Probst
    Oct 24, 2022

    Prostatic Tumors Trial in Worldwide (Pembrolizumab, Olaparib, Abiraterone acetate)

    Active, not recruiting
    • Prostatic Neoplasms
    • Pembrolizumab
    • +4 more
    • Fullerton, California
    • +192 more
    Oct 17, 2022

    Prostate Cancer, Adenocarcinoma, Prostatic Tumors Trial (bpMRI, Image-Fusion targeted and systematic Biopsy)

    Not yet recruiting
    • Prostate Cancer
    • +4 more
    • bpMRI
    • Image-Fusion targeted and systematic Biopsy
    • (no location specified)
    Oct 7, 2022

    Prostatic Tumors, Self-Management Trial in Keelung, Taoyuan (Self-management program, Information package)

    Recruiting
    • Prostatic Neoplasms
    • Self-Management
    • Self-management program
    • Information package
    • Keelung, Taiwan
    • +1 more
    Sep 27, 2022

    Prostatic Tumors Trial in Bronx (Abiraterone Acetate, Prednisone)

    Active, not recruiting
    • Prostatic Neoplasms
    • Bronx, New York
      Montefiore Medical Center
    Sep 22, 2022

    Prostatic Tumors Trial in New York, Myrtle Beach, Houston (ORIC-101, enzalutamide 40 MG oral capsule [Xtandi])

    Active, not recruiting
    • Prostatic Neoplasms
    • ORIC-101
    • enzalutamide 40 MG oral capsule [Xtandi]
    • New York, New York
    • +2 more
    Sep 22, 2022

    Prostatic Tumors Trial in San Francisco (Pembrolizumab, SD-101, Leuprolide acetate)

    Active, not recruiting
    • Prostatic Neoplasms
    • San Francisco, California
      University of California San Francisco
    Sep 20, 2022

    Prostatic Tumors Trial in China (Apalutamide, Placebo, Androgen-deprivation Therapy (ADT))

    Recruiting
    • Prostatic Neoplasms
    • Beijing, China
    • +29 more
    Aug 15, 2022

    Prostate Cancer Among Those WithPositive Family History

    Completed
    • Prostate Cancer
    • +2 more
      • Nasiriyah, Thi Qar, Iraq
        Al-Dar medical Center
      Aug 17, 2022

      Prostatic Tumors Trial in United States (CC-94676)

      Recruiting
      • Prostatic Neoplasms
      • Birmingham, Alabama
      • +30 more
      Aug 17, 2022